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oral agents only (43%), and 25% contained insulin. Of patients using CANA in com-
bination with other AHAs, 20% discontinued use of at least 1 AHA during follow-
up. CANA index dose was 100mg for 65% of the population and 300mg for the 
remainder; 30% of patients initially observed on CANA 100mg titrated to 300mg. 
Among patients with A1C ≥ 7.0% at baseline, the proportion of patients with A1C 
< 7% and < 8% increased from 0% (baseline) to 21% (follow-up) and 30% (baseline) to 
61% (follow-up), respectively; those with A1C ≥ 9.0% decreased from 33% (baseline) 
to 16% (follow-up). CONCLUSIONS: CANA was often prescribed as add-on therapy 
to multiple AHAs with one-fifth of patients discontinuing use of other AHAs after 
CANA was added to their treatment regimen. In patients with uncontrolled A1Cs, 
their A1Cs improved following treatment with CANA.
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OBJECTIVES: Given the progressive nature of T2DM, treatment is often characterised 
by gradual intensification, ultimately requiring multiple daily insulin injections. 
CANA and DAPA are agents with activity on SGLT2 that may delay the need for 
insulin. Network meta-analyses (NMAs) have found that CANA 300 mg lowers HbA1c 
more than DAPA in dual and triple therapy. Mechanistic differences support these 
results. Specifically, CANA 300 mg has been shown to reduce the renal threshold for 
glucose excretion more than DAPA 10 mg, resulting in 25% greater 24-hour urinary 
glucose excretion. In addition, unlike DAPA, CANA 300 mg may transiently block 
intestinal SGLT1, delaying glucose absorption and reducing postprandial glucose. 
This study evaluates differences in time to insulin initiation using CANA versus 
DAPA as dual and triple therapy in the Irish healthcare setting. METHODS: A vali-
dated model (ECHO-T2DM) was used to simulate 40-year costs and outcomes asso-
ciated with canagliflozin (100 mg, titrated to 300 mg in patients requiring tighter 
glycaemic control) compared to DAPA (10 mg). Insulin rescue therapy was initiated 
when HbA1c exceeded 7.5%. The CANA RCTs and the NMAs were sourced for ini-
tial patient characteristics and treatment effects, respectively. RESULTS: In dual 
therapy, insulin rescue was delayed by 1.7 years on average for CANA titrated to goal 
(4.8 years) versus DAPA (3.1 years). In triple therapy, insulin therapy was delayed by 
1.8 years on average for CANA titrated to goal (5.1 years) versus DAPA (3.3 years). 
Much of the difference was driven by the ability to titrate to CANA 300 mg for addi-
tional glycaemic control. CONCLUSIONS: These simulations suggest that treatment 
with CANA versus DAPA could delay insulin initiation by 55% in both dual and triple 
therapy. This difference may translate into delays in undesirable health outcomes 
and the financial burden associated with injectables in actual practice.
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OBJECTIVES: The use of insulin analogues for the treatment of diabetes mellitus 
type 1 (DM1) has been widespread, but the real therapeutic benefits need more 
evidences. The aim of this study was to compare the efficacy and safety of insulin 
analogues with human insulin preparations in the treatment of DM1. METHODS: 
Systematic review with meta-analysis of randomized controlled trials (RCTs) avail-
able in PUBMED, LILACS, CENTRAL (accessed February/2014), including manual and 
gray literature search. The meta-analysis was performed using Review Manager® 
5.2 software using random effects model. Outcomes considered were: concentra-
tion(%) of glycated hemoglobin (Hb1Ac), blood or plasma glucose concentrations 
and occurrence of hypoglycemic episodes. Risk of bias was assessed according the 
recommendations of the Cochrane Collaboration. RESULTS: In a total of 36,673 
publications achieved, 35 studies were included: 14 studies compared glargine with 
NPH, 02 (Glargine vs. Detemir), 08 (NPH vs. Detemir), 04 (regular insulin vs Aspart), 
06 (regular insulin vs. Lispro) and 01 (Regular Insulin vs. Glulisine). The insulin 
analogues showed no differences (p< 0,05) compared to human insulin prepara-
tions in relation to Hb1Ac (except Aspart vs regular insulin: favored Aspart) and 
occurrence of hypoglycemic episodes (except Detemir vs. NPH: favored Detemir). 
Glargine, Detemir and Lispro compared to human insulin preparations showed 
slightly improved fasting or post-prandial blood glucose concentrations, however 
this outcome had no ability to influence the overall glycemic control measured by 
Hb1Ac. Most studies showed poor methodological quality and conflicts of inter-
est. CONCLUSIONS: There is poor evidence for the recommendation of first-line 
therapy using analogues instead of human insulin preparations, which efficacy and 
long-term security is better known. The analogues for the treatment of DM1 should 
be better assessed on randomized clinical trials with good methodological quality, 
as well as review of pharmacovigilance data and observational studies in order to 
assess the long-term safety profile.
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OBJECTIVES: Individuals with an A1C between 5.7% and 6.4%, impaired fasting glu-
cose (from 100mg/dl [5.6mmol/l] and 125mg/dl [6.9mmol/l] or glucose impaired toler-
ance (oral glucose tolerance test [2-hour] between 140mg/dl [7.8mmol/l] and 199mg/dl 
[11.0mmol/l]), classified as having prediabetes are at increased risk for development 
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OBJECTIVES: Dipeptidyl peptidase-4 inhibitors (DPP4I) include sitagliptin, saxaglip-
tin, vildagliptin and linagliptin. Except for linagliptin, dosage adjustments based 
on renal function are recommended to avoid adverse events (e.g., hypoglycemia). 
However, data on the effect of DPP4I on hemoglobin A1c (HbA1c) in patients with 
renal impairment is sparse. This meta-analysis seeks to determine the effect of 
DPP-4I on HbA1c in patients with chronic kidney disease (CKD). METHODS: Multiple 
databases using the generic name of each DPP4I plus the following search terms 
“renal”, “renal impairment”, chronic kidney disease”, “dialysis”, were queried for 
clinical trial data. Qualitative assessment and quantitative analyses were per-
formed. RESULTS: Eleven citations met inclusion criteria. Studies included 1,704 
participants (10.7% on dialysis), 48-79 years of age, 56% men, 56% Caucasians. Four 
studies compared DPP4I with sulfonylurea (glipizide or glimepiride), five compared 
DPP4I with placebo, two compared DPP4I with placebo for initial 12-weeks and then 
switched to sulfonylurea for 40-42 weeks. Meta-analysis showed DPP-4I caused a 
modest but significant reduction in HbA1c of 0.46% [95% Confidence Interval (CI) 
-0.58, -0.33], p< 0.00001, (I2= 12%), over 12-54 weeks (in patients not on dialysis). In 
placebo-comparator studies, reduction in HbA1c over 12-24 weeks was -0.54% [95%CI 
-0.67, -0.40], p< 0.00001, without heterogeneity. In sulfonylurea-comparator studies, 
DPP-4I did not significantly reduce HbA1c at week 24 (-0.09 [95%CI -0.26, 0.09]) but 
caused a small but significant reduction by weeks 52-54 (-0.19% [95%CI -0.37, -0.00], 
p= 0.04), without heterogeneity. In patients on dialysis, with either comparator (pla-
cebo or glipizide), DPP4I did not significantly reduce HbA1c after 52-54 weeks (0.11 
[95%CI -0.20, 0.41]). CONCLUSIONS: DPP4I in patients with moderate-severe renal 
impairment is associated with a modest reduction of HbA1c versus placebo, but 
not when compared with sulfonylureas or when used in patients on dialysis. It is 
unclear if this modest reduction is worth the high cost of DPP4I in patients with CKD.
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OBJECTIVES: Type 2 diabetes is a progressive disease and most patients experience 
deterioration in glycemic control over time necessitating the use of combination 
therapy. We sought to determine the comparative efficacy and safety of third-line 
antidiabetic agents in patients with type 2 diabetes after failure of metformin 
and TZD therapy. METHODS: We performed a literature search of MEDLINE and 
CENTRAL through May 2014 and included randomized controlled trials (RCTs) of 
≥ 12-weeks duration evaluating the addition of a noninsulin agent in patients with 
type 2 diabetes inadequately controlled on stable, optimized metformin and TZD 
therapy (≥ 1500mg metformin and ≥ 50% maximum TZD dose for ≥ 4 weeks). Network 
meta-analysis was performed on identified trials. Endpoints of interest were 
changes from baseline in HbA1c, body weight, systolic blood pressure (SBP); and 
the risk of hypoglycemia, urinary (UTI) and genital tract infection (GTI). RESULTS: 
Eleven RCTs evaluating dipeptidyl peptidase-4 (DPP-4) inhibitors (linagliptin, sitag-
liptin), sulfonylureas (SUs), (glibenclamide, glimepiride), glucagon-like peptide-1 
(GLP-1) analogs (exenatide, liraglutide, dulaglutide, taspoglutide) and sodium glu-
cose cotransporter-2 (SGLT2) inhibitors (canagliflozin, empagliflozin) were included. 
All agents analyzed reduced HbA1c vs placebo (range, 0.55-1.17%). All SUs were 
associated with significant weight gain (range, 3.31-7.29 kg), while significant weight 
loss was seen with all GLP-1 analogs (range, 1.53-2.2 kg) and SGLT-2 inhibitors (range, 
2.08-2.95 kg). A reduction in SBP was seen in canagliflozin and GLP-1 analogs (range, 
2.39-5.05 mmHg). The relative risk (RR) of confirmed hypoglycemia was significantly 
increased with dulaglutide, exenatide and glimepiride vs. placebo (RR range, 2.65-
6.17); and was higher (RR> 1.0) than all other agents except linagliptin. No agent 
reported an increased risk for UTI or GTI vs. placebo. CONCLUSIONS: In conclu-
sion, when added to stable, optimized metformin and TZD therapy, all noninsulin 
antidiabetic agents reduced HbA1c, but differed in their effects on body weight, 
hypoglycemia and SBP.
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OBJECTIVES: Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, 
has been shown to improve glycemic control in clinical trials. This study describes 
the treatment patterns of antihyperglycemic agents (AHAs) among patients with 
T2DM receiving CANA in a real-world setting. METHODS: This retrospective cohort 
study used data from a large US health plan for commercial and Medicare Advantage 
enrollees age ≥ 18 years with T2DM that filled CANA between April-October 2013 
(first 7 months on the market). Six-month baseline and follow-up data were evalu-
ated. Concomitant AHA use was defined as having at least 2 prescriptions, with 1 fill 
during baseline and 1 fill on/after CANA initiation without a ≥ 60-day therapy gap. 
Discontinuation was defined as a ≥ 60-day therapy gap. RESULTS: In this sample 
(n= 4017), 43% were female and average age was 56 years; 826 had baseline and 
follow-up A1C available. Approximately 30% of patients used CANA concomitantly 
with 1 other AHA, while 50% used CANA concomitantly with ≥ 2 other AHAs; the 
remaining 20% used CANA alone. The most common baseline regimens comprised 
